Overview Dividends

(SIGA) SIGA Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8269171067

Antiviral, Smallpox, TPOXX, Health Security

SIGA EPS (Earnings per Share)

EPS (Earnings per Share) of SIGA over the last years for every Quarter: "2020-09": 0.31, "2020-12": 0.26, "2021-03": -0.02, "2021-06": -0.0034, "2021-09": -0.04, "2021-12": 0.98, "2022-03": -0.01, "2022-06": 0.03, "2022-09": 0.45, "2022-12": -0.01, "2023-03": -0.01, "2023-06": -0.04, "2023-09": -0.01, "2023-12": 1.0164, "2024-03": 0.1436, "2024-06": 0.0255, "2024-09": 0.0187, "2024-12": 0.6409, "2025-03": -0.0057, "2025-06": 0.49, "2025-09": 0,
EPS Growth (3Y CAGR): 10.33%
EPS Trend (3Y Correlation): 20.5%

SIGA Revenue

Revenue of SIGA over the last years for every Quarter: 2020-09: 44.261407, 2020-12: 37.729355, 2021-03: 4.813744, 2021-06: 8.653289, 2021-09: 4.846172, 2021-12: 115.357248, 2022-03: 10.539299, 2022-06: 16.667045, 2022-09: 72.211127, 2022-12: 11.358139, 2023-03: 8.323025, 2023-06: 5.878166, 2023-09: 9.235171, 2023-12: 116.480859, 2024-03: 25.429855, 2024-06: 21.810891, 2024-09: 10.009781, 2024-12: 81.469, 2025-03: 7.040815, 2025-06: 81.120004, 2025-09: null,
Revenue Growth (3Y CAGR): 4.32%
Revenue Trend (3Y Correlation): 19.0%

Description: SIGA SIGA Technologies October 24, 2025

SIGA Technologies, Inc. (NASDAQ:SIGA) is a commercial-stage biopharma focused on the U.S. health-security market, best known for its FDA-approved antiviral TPOXX, the only licensed treatment for smallpox.

Key metrics as of the latest filing (Q2 2024): cash and short-term investments of roughly $140 million, a net loss of $32 million for the trailing twelve months, and a market-cap near $350 million. The company’s revenue is driven almost entirely by government contracts for TPOXX, which together with the broader biodefense budget (projected to grow at ~4% CAGR) constitute its primary economic driver.

Sector trends that affect SIGA include heightened federal spending on pandemic preparedness and the expanding “health-security” niche, which has attracted increased R&D incentives and potential partnership opportunities with defense contractors.

For a deeper, data-rich analysis of SIGA’s valuation and peer landscape, you may find ValueRay’s research tools helpful.

SIGA Stock Overview

Market Cap in USD 593m
Sub-Industry Pharmaceuticals
IPO / Inception 1997-09-09

SIGA Stock Ratings

Growth Rating 45.6%
Fundamental 84.5%
Dividend Rating 84.6%
Return 12m vs S&P 500 8.13%
Analyst Rating -

SIGA Dividends

Dividend Yield 12m 7.12%
Yield on Cost 5y 11.41%
Annual Growth 5y 15.47%
Payout Consistency 98.8%
Payout Ratio 53.3%

SIGA Growth Ratios

Growth Correlation 3m -52.8%
Growth Correlation 12m 71%
Growth Correlation 5y 31%
CAGR 5y 7.69%
CAGR/Max DD 3y (Calmar Ratio) 0.14
CAGR/Mean DD 3y (Pain Ratio) 0.22
Sharpe Ratio 12m -0.08
Alpha 9.37
Beta 0.978
Volatility 44.63%
Current Volume 315.8k
Average Volume 20d 303.7k
Stop Loss 8.1 (-3.9%)
Signal -0.02

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (82.2m TTM) > 0 and > 6% of Revenue (6% = 10.8m TTM)
FCFTA 0.51 (>2.0%) and ΔFCFTA 12.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 114.9% (prev 89.67%; Δ 25.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.51 (>3.0%) and CFO 119.1m > Net Income 82.2m (YES >=105%, WARN >=100%)
Net Debt (-181.9m) to EBITDA (103.1m) ratio: -1.77 <= 3.0 (WARN <= 3.5)
Current Ratio 10.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (71.7m) change vs 12m ago -0.01% (target <= -2.0% for YES)
Gross Margin 73.13% (prev 79.83%; Δ -6.70pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 83.95% (prev 89.77%; Δ -5.83pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -20.21 (EBITDA TTM 103.1m / Interest Expense TTM -5.05m) >= 6 (WARN >= 3)

Altman Z'' 7.27

(A) 0.88 = (Total Current Assets 229.2m - Total Current Liabilities 22.7m) / Total Assets 235.3m
(B) -0.13 = Retained Earnings (Balance) -31.3m / Total Assets 235.3m
(C) 0.48 = EBIT TTM 102.1m / Avg Total Assets 214.0m
(D) -1.20 = Book Value of Equity -31.3m / Total Liabilities 26.0m
Total Rating: 7.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 84.45

1. Piotroski 4.50pt = -0.50
2. FCF Yield 28.96% = 5.0
3. FCF Margin 66.25% = 7.50
4. Debt/Equity 0.00 = 2.50
5. Debt/Ebitda -1.77 = 2.50
6. ROIC - WACC (= 28.20)% = 12.50
7. RoE 40.55% = 2.50
8. Rev. Trend 19.02% = 1.43
9. EPS Trend 20.50% = 1.03

What is the price of SIGA shares?

As of November 06, 2025, the stock is trading at USD 8.43 with a total of 315,771 shares traded.
Over the past week, the price has changed by +3.69%, over one month by +2.43%, over three months by +27.73% and over the past year by +28.59%.

Is SIGA Technologies a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, SIGA Technologies (NASDAQ:SIGA) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 84.45 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SIGA is around 8.55 USD . This means that SIGA is currently overvalued and has a potential downside of 1.42%.

Is SIGA a buy, sell or hold?

SIGA Technologies has no consensus analysts rating.

What are the forecasts/targets for the SIGA price?

Issuer Target Up/Down from current
Wallstreet Target Price 17.5 107.9%
Analysts Target Price 17.5 107.9%
ValueRay Target Price 9.6 14.2%

SIGA Fundamental Data Overview November 03, 2025

Market Cap USD = 592.9m (592.9m USD * 1.0 USD.USD)
P/E Trailing = 7.2632
P/E Forward = 5.6275
P/S = 3.3005
P/B = 3.0618
Beta = 0.978
Revenue TTM = 179.6m USD
EBIT TTM = 102.1m USD
EBITDA TTM = 103.1m USD
Long Term Debt = 570.4k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 570.4k USD (from shortTermDebt, last quarter)
Debt = 570.4k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -181.9m USD (from netDebt column, last quarter)
Enterprise Value = 411.0m USD (592.9m + Debt 570.4k - CCE 182.5m)
Interest Coverage Ratio = -20.21 (Ebit TTM 102.1m / Interest Expense TTM -5.05m)
FCF Yield = 28.96% (FCF TTM 119.0m / Enterprise Value 411.0m)
FCF Margin = 66.25% (FCF TTM 119.0m / Revenue TTM 179.6m)
Net Margin = 45.75% (Net Income TTM 82.2m / Revenue TTM 179.6m)
Gross Margin = 73.13% ((Revenue TTM 179.6m - Cost of Revenue TTM 48.3m) / Revenue TTM)
Gross Margin QoQ = 68.50% (prev 48.57%)
Tobins Q-Ratio = 1.75 (Enterprise Value 411.0m / Total Assets 235.3m)
Interest Expense / Debt = 156.1% (Interest Expense 890.6k / Debt 570.4k)
Taxrate = 24.94% (11.8m / 47.3m)
NOPAT = 76.6m (EBIT 102.1m * (1 - 24.94%))
Current Ratio = 10.09 (Total Current Assets 229.2m / Total Current Liabilities 22.7m)
Debt / Equity = 0.00 (Debt 570.4k / totalStockholderEquity, last quarter 209.3m)
Debt / EBITDA = -1.77 (Net Debt -181.9m / EBITDA 103.1m)
Debt / FCF = -1.53 (Net Debt -181.9m / FCF TTM 119.0m)
Total Stockholder Equity = 202.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 34.92% (Net Income 82.2m / Total Assets 235.3m)
RoE = 40.55% (Net Income TTM 82.2m / Total Stockholder Equity 202.7m)
RoCE = 50.24% (EBIT 102.1m / Capital Employed (Equity 202.7m + L.T.Debt 570.4k))
RoIC = 37.81% (NOPAT 76.6m / Invested Capital 202.7m)
WACC = 9.61% (E(592.9m)/V(593.5m) * Re(9.62%) + (debt cost/tax rate unavailable))
Discount Rate = 9.62% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.46%
[DCF Debug] Terminal Value 76.49% ; FCFE base≈100.9m ; Y1≈124.5m ; Y5≈212.4m
Fair Price DCF = 38.12 (DCF Value 2.73b / Shares Outstanding 71.6m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 20.50 | EPS CAGR: 10.33% | SUE: 0.0 | # QB: 0
Revenue Correlation: 19.02 | Revenue CAGR: 4.32% | SUE: 0.44 | # QB: 0

Additional Sources for SIGA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle